Randomised trial
-
Adding chemotherapy and bevacizumab delayed progression in DNA repair-deficient bowel cancer
In 82 people with previously untreated metastatic colorectal cancer that was mismatch repair-deficient or microsatellite instability-high, adding mFOLFOX6 chemotherapy and bevacizumab to atezolizumab lowered the risk of progression…
-
Resistance training may blunt a biological aging signal during chemotherapy
In a randomised trial of adults receiving adjuvant chemotherapy for stage II-III colon cancer, a DNA-based aging measure called GrimAge rose by 0.29 standard deviations per six months…
-
Hybrid resistance training was manageable, creatine added no clear benefit
In this 27-person randomized pilot trial, 24 participants completed 10 weeks of supervised hybrid resistance training, with 91.5% average exercise dose completion and 94% supplement adherence. Creatine did…
-
Blood test led to more potentially curative recurrence treatment
In a 584-person randomised trial after surgery for nonmetastatic colorectal cancer, surveillance guided by a blood test for tumour DNA led to curative-intent treatment in 48.1% of recurrences,…
-
Adding irinotecan brought more side effects without improving rectal cancer outcomes
At 36 months, disease-free survival was 68% with irinotecan plus capecitabine chemoradiotherapy and 67% with capecitabine chemoradiotherapy alone, hazard ratio 0.91 (95% CI 0.68–1.23). This phase 3 randomised…
-
Higher-dose vitamin D did not slow metastatic colorectal cancer
Among 455 people starting treatment for metastatic colorectal cancer, median progression-free survival was 11.8 months with high-dose vitamin D3 and 10.3 months with standard-dose vitamin D3, a difference…
-
Nutrition drinks were linked to fewer chemotherapy changes after surgery
In a 157-person randomised trial, chemotherapy modifications occurred in 17.5% of patients given oral nutritional supplements plus dietary advice, versus 35.1% given dietary advice alone. Five-year all-cause mortality…
-
Short radiotherapy and chemotherapy improved five-year survival in rectal cancer
At five years, overall survival was 78.1% with short-course radiotherapy followed by chemotherapy, compared with 69.7% with long-course chemoradiotherapy, HR 0.739 (95% CI 0.550 to 0.993). Disease-free survival…
-
Tislelizumab regimen reached 45.3% pathological complete response in rectal cancer
In this 118-patient randomised phase II trial, adding tislelizumab to short-course radiotherapy and CAPOX chemotherapy was associated with a higher pathological complete response rate than the same treatment…
-
Cetuximab-irinotecan produced 18.8 versus 10.4 months median survival
In a 68-patient exploratory randomised trial, rechallenge with cetuximab plus irinotecan produced longer median progression-free and overall survival than regorafenib. The result is promising but comes from one…